62 related articles for article (PubMed ID: 32500783)
1. Long-term follow-up of oxaliplatin-induced liver damage in patients with colorectal cancer.
Cha DI; Song KD; Ha SY; Hong JY; Hwang JA; Ko SE
Br J Radiol; 2021 Jul; 94(1123):20210352. PubMed ID: 34133224
[TBL] [Abstract][Full Text] [Related]
2. Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.
Ohta R; Yamada T; Hara K; Iwai T; Tanakaya K; Ishibashi K; Yoshimatsu K; Kosugi C; Tsubaki M; Nakajima H; Oya M; Yoshida H; Koda K; Ishida H
Int J Clin Oncol; 2020 Dec; 25(12):2075-2082. PubMed ID: 32785799
[TBL] [Abstract][Full Text] [Related]
3. Impact of visceral adipose tissue on the accuracy of T-staging by CT in colon cancer.
Liu LH; Zhou GF; Zhou JJ; Rao SX; Zeng MS
Eur J Radiol; 2021 Jan; 134():109400. PubMed ID: 33254063
[TBL] [Abstract][Full Text] [Related]
4. Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China.
Zhu L; Zhang CY; Li DP; Chen HB; Ma J; Gao H; Ye Y; Wang JY; Fu PP; Lin G
Acta Pharmacol Sin; 2021 Aug; 42(8):1212-1222. PubMed ID: 33154553
[TBL] [Abstract][Full Text] [Related]
5. Application of Gd-EOB-DTPA-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma.
Li XQ; Wang X; Zhao DW; Sun J; Liu JJ; Lin DD; Yang G; Liu H; Xia ZY; Jia CY; Li HJ
World J Surg Oncol; 2020 Aug; 18(1):219. PubMed ID: 32828123
[TBL] [Abstract][Full Text] [Related]
6. Hepatobiliary phase liver MR imaging findings after Oxaliplatin-based chemotherapy in cancer patients.
Ünal E; Karaosmanoğlu AD; Ozmen MN; Akata D; Karcaaltincaba M
Abdom Radiol (NY); 2018 Sep; 43(9):2321-2328. PubMed ID: 29427046
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Zhu C; Ren X; Liu D; Zhang C
Toxicology; 2021 Aug; 460():152882. PubMed ID: 34352347
[TBL] [Abstract][Full Text] [Related]
8. Gd-EOB-DTPA-enhanced MR findings in chemotherapy-induced sinusoidal obstruction syndrome in colorectal liver metastases.
Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
J Int Med Res; 2020 Jun; 48(6):300060520926031. PubMed ID: 32500783
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance assessment of sinusoidal obstruction syndrome after neoadjuvant chemotherapy for colorectal liver metastases is not reproducible.
Staal FC; Beets-Tan RG; Heeres BC; Houwers J; de Boer M; van Dorth D; Lambregts DM; Maas M
Acta Radiol; 2021 Sep; 62(9):1133-1141. PubMed ID: 32972213
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases.
Shin NY; Kim MJ; Lim JS; Park MS; Chung YE; Choi JY; Kim KW; Park YN
Eur Radiol; 2012 Apr; 22(4):864-71. PubMed ID: 22108766
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome.
Yoneda N; Matsui O; Ikeno H; Inoue D; Yoshida K; Kitao A; Kozaka K; Kobayashi S; Gabata T; Ikeda H; Nakamura K; Ohta T
Abdom Imaging; 2015 Oct; 40(8):3099-103. PubMed ID: 26187715
[TBL] [Abstract][Full Text] [Related]
12. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
13. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases.
Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB
AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
